1.
Economopoulos KP,
Sergentanis TN,
Tsivgoulis G,
et al.
Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes.
Stroke 2011; 42:687–692.
2.
Gro¨schel K,
Riecker A,
Schulz JB,
et al.
Systematic review of early recurrent stenosis after carotid angioplasty and stenting.
Stroke 2005; 36:367–373.
3.
Nederkoorn PJ,
Brown MM.
Optimal cut-off criteria for duplex ultrasound for the diagnosis of restenosis in stented carotid arteries: review and protocol for a diagnostic study.
BMC Neurol 2009; 9:36.
4.
Brott TG,
Halperin JL,
Abbara S,
et al.
2011 ASA/ACCF/AHA/AANN/ AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executivesummary— a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,
and the American Stroke Association,
American Association of Neuroscience Nurses,
American Association of Neurological Surgeons,
American College of Radiology,
American Society of Neuroradiology,
Congress of Neurological Surgeons,
Society of Atherosclerosis Imaging and Prevention,
Society for Cardiovascular Angiography and Interventions,
Society of Interventional Radiology,
Society of NeuroInterventional Surgery,
Society for Vascular Medicine,
and Society for Vascular Surgery developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography.
J Am Coll Cardiol 2011; 57:16–94.
5.
Michos ED,
Ardehali R,
Blumenthal RS,
et al.
Aspirin and clopidogrel resistance.
Mayo Clin Proc 2006; 81: 518-26.
6.
Takigawa T,
Matsumaru Y,
Hayakawa M et.
al.
Cilostazol reduces restenosis after carotid artery.
J Vasc Surg.
2010; 51:51-6.
7.
Takayama K,
Taoka T,
Nakagawa H,
et al.
Effect of cilostazol in preventing restenosis after carotid artery stenting using the carotid wallstent: a multicenter retrospective study.
AJNR Am J Neuroradiol.
2012; 33:2167-70.
8.
Wasser K,
Schnaudigel S,
Wohlfahrt J,
Psychogios MN,
Schramm P,
Knauth M,
Gröschel K.
Clinical impact and predictors of carotid artery in-stent restenosis.
J Neurol.
2012; 259:1896-902.
9.
Biondi-Zoccai GG,
Lotrionte M,
Anselmino M,
et al.
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.
Am Heart J 2008; 155:1081–9.
10.
Douglas JS Jr,
Holmes DR Jr,
Kereiakes DJ,
et al.
Coronary stent restenosis in patients treated with cilostazol.
Circulation 2005; 112:2826–32.
11.
Soga Y,
Iida O,
Hirano K,
et al.
Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
Catheter Cardiovasc Interv.
2012; 79:541-8.
12.
Kimura Y,
Tani T,
Kanbe T,
et al.
Effect of cilostazol on platelet aggregation and experimental thrombosis.
Arzneimittelforschung 1985; 35:1144–9.
13.
Ikeda Y,
Kikuchi M,
Murakami H,
et al.
Comparison of the inhibitory effects of cilostazol,
acetylsalicylic acid and ticlopidine on platelet functions ex vivo.
Arzneimittelforschung/Drug Res 1987; 37:563–6.
14.
Yasunaga K,
Mase K.
Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.
Arzneimittelforschung/Drug Res 1985; 35:1189–92.
15.
Norgren L,
Hiatt WR,
Dormandy JA,
et al.
TASC II Working Group.
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).
J Vasc Surg.
2007;45:S5-67.
16.
McBride W,
Lange RA,
Hillis LD.
Restenosis after successful coronary angioplasty: Pathophysiology and prevention.
N Engl J Med 1988; 318:1734–7.
17.
Clowes AW,
Schwartz SM.
Significance of quiescent smooth muscle cell migration in the injured rat carotid artery.
Circ Res 1985; 56:139–145.
18.
Morishita R.
A scientific rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis.
Atheroscler Suppl 2005; 6:41–46.
19.
Shin HK,
Kim YK,
Kim KY,
et al.
Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: Prevention by cilostazol.
Circulation 2004; 109:1022–8.
20.
Oida K,
Ebata K,
Kanehara H,
et al.
Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers.
J Atheroscler Thromb 2003; 10:93–98.